Le Lézard
Classified in: Business, Covid-19 virus
Subject: ATY

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NRx Pharmaceuticals, Inc, of Class Action Lawsuit and Upcoming Deadline - NRXP; NRXPW


NEW YORK, Jan. 21, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP; NRXPW) and certain of its officers. The class action, filed in the United States District Court for the District of Delaware, and docketed under 22-cv-00066, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired NRx securities between June 1, 2021 and November 4, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased or otherwise acquired NRx during the Class Period, you have until March 21, 2022 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here for information about joining the class action]

NRx is a clinical-stage small molecule pharmaceutical company that develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The Company's products include, among others, ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure.

In June 2021, NRx announced that it filed an application with U.S. Food and Drug Administration ("FDA") requesting Emergency Use Authorization ("EUA") for ZYESAMI (Aviptadil-acetate) to treat critically ill COVID-19 patients suffering with respiratory failure (the "ZYESAMI EUA Application").

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the ZYESAMI EUA Application contained insufficient data regarding the potential benefits and risks of ZYESAMI; (ii) accordingly, the FDA was unlikely to approve the ZYESAMI EUA Application in its present form; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

On November 4, 2021, NRx issued a press release "announc[ing] that the [FDA] has declined to issue an [EUA] for ZYESAMI® (aviptadil). The FDA stated that it was unable to issue the EUA at this time due to insufficient data regarding the known and potential benefits of the medicine and the known and potential risks of ZYESAMI in patients suffering from Critical COVID-19 with respiratory failure."

On this news, NRx's stock price fell $2.27 per share, or 25.45%, to close at $6.65 per share on November 5, 2021.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected] 
888-476-6529 ext. 7980

SOURCE Pomerantz LLP


These press releases may also interest you

at 23:34
Taiwanese biotech outfit AcadeMab has broken new ground in the development of COVID immunotherapies through the development of a potentially life-saving monoclonal antibodies for COVID-19 patients using single B cell technology, shows the best...

at 23:00
The Very Good Food Company Inc. ("VERY GOOD" or the "Company"), was notified on May 20, 2022, by The NASDAQ Stock Market LLC ("NASDAQ") that since the Company had not yet filed its Annual Report on Form 20-F (the "Form 20-F") for the year ended...

at 22:13
Indonesia and the U.N. Office for Disaster Risk Reduction (UNDRR) host the Seventh Session of the Global Platform for Disaster Risk Reduction (GP2022) in Bali, Indonesia, from 23 to 28 May 2022 as informed by Ministry of Communications and...

at 21:55
Wallbridge Mining Company Limited ("Wallbridge" or the "Company") held its Annual and Special Meeting of Shareholders (the "Meeting") on May 25, 2022. A total of 523,233,979 shares or 59.3% of the outstanding shares of the Company were...

at 20:56
NewsBlaze is excited to announce the release of NewsBlaze writer and editor Ernest Dempsey's first solo Hail To My Fairyland. The song was released via the popular online music distributor CD Baby on Monday, May 23, 2022....

at 20:30
Harborside Inc. ("Harborside" or the "Company") , a California-focused, vertically integrated cannabis enterprise, today filed its interim financial statements and management's discussion and analysis for the three months...



News published on 21 january 2022 at 19:25 and distributed by: